

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 38/17, 39/395, G01N 33/577, 33/68		(11) International Publication Number: WO 97/03687																												
AI		(43) International Publication Date: 6 February 1997 (06.02.97)																												
(21) International Application Number: PCT/US96/12010 (22) International Filing Date: 19 July 1996 (19.07.96) (30) Priority Data: 08/505,606                      21 July 1995 (21.07.95)                      US (69) Parent Application or Grant (63) Related by Continuation US Filed on                      21 July 1995 (21.07.95) (71) Applicant (for all designated States except US): BIOGEN, INC. [US/US]: 14 Cambridge Center, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BROWNING, Jeffrey, L. [US/US]: 32 Milton Road, Brookline, MA 02146 (US). BENJAMIN, Christopher, D. [US/US]: 2 Oak Hill Lane, Beverly, MA 01915 (US). HOCHMAN, Paula, S. [US/US]: 95 Collidge Street, Brookline, MA 02146 (US). (74) Agent: FLYNN, Kerry, A.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).		(51) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.																												
(54) Title: SOLUBLE LYMPHOTOXIN- $\beta$ RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE  <table border="0"> <tr> <td>1</td> <td>SQPOAVFPYA</td> <td>SENQTCRQDE</td> <td>KEYYZPQERR</td> <td>CCSRCPFGTY</td> <td>VSAKCSRIRD</td> <td>50</td> </tr> <tr> <td>51</td> <td>TVCATCAENS</td> <td>YNEHWYI/TI</td> <td>COLCRPCDFV</td> <td>HGLEELAPCT</td> <td>SKRRTQCRQ</td> <td>100</td> </tr> <tr> <td>101</td> <td>PEMPCAAWAL</td> <td>ECTECCLLSD</td> <td>CPFGTEAELE</td> <td>DEVGAGNNEC</td> <td>VECTAGHPON</td> <td>150</td> </tr> <tr> <td>151</td> <td>TSSPSARCQP</td> <td>HTACENQGLV</td> <td>EAAPGTAQSD</td> <td>TTCNPLEPL</td> <td>PPEMSGT</td> <td>197</td> </tr> </table>			1	SQPOAVFPYA	SENQTCRQDE	KEYYZPQERR	CCSRCPFGTY	VSAKCSRIRD	50	51	TVCATCAENS	YNEHWYI/TI	COLCRPCDFV	HGLEELAPCT	SKRRTQCRQ	100	101	PEMPCAAWAL	ECTECCLLSD	CPFGTEAELE	DEVGAGNNEC	VECTAGHPON	150	151	TSSPSARCQP	HTACENQGLV	EAAPGTAQSD	TTCNPLEPL	PPEMSGT	197
1	SQPOAVFPYA	SENQTCRQDE	KEYYZPQERR	CCSRCPFGTY	VSAKCSRIRD	50																								
51	TVCATCAENS	YNEHWYI/TI	COLCRPCDFV	HGLEELAPCT	SKRRTQCRQ	100																								
101	PEMPCAAWAL	ECTECCLLSD	CPFGTEAELE	DEVGAGNNEC	VECTAGHPON	150																								
151	TSSPSARCQP	HTACENQGLV	EAAPGTAQSD	TTCNPLEPL	PPEMSGT	197																								
(57) Abstract  This invention relates to compositions and methods comprising "lymphotoxin- $\beta$ receptor blocking agents", which block lymphotoxin- $\beta$ receptor signalling. Lymphotoxin- $\beta$ receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin- $\beta$ receptor extracellular domain that act as lymphotoxin- $\beta$ receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin- $\beta$ receptor or its ligand, surface lymphotoxin, that act as lymphotoxin- $\beta$ receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT- $\beta$ receptor signalling is provided.																														

BEST AVAILABLE COPY